| Literature DB >> 31884848 |
Jie Han1, Chaoyang Huang1, Jiukun Jiang2, Dongmei Jiang3.
Abstract
OBJECTIVES: Autophagy is divided into three phases: autophagosome engulfment of intracellular organelles and proteins, autophagosome fusion with lysosomes, and autolysosome degradation. The farnesyl pyrophosphate synthase inhibitor ibandronate (IBAN) has in vivo cardioprotective properties, potentially via anti-oxidant effects. Whether autophagy is involved in the cardioprotective effect of IBAN remains unexplored.Entities:
Keywords: Atg7; Autophagy; FPPS; HUVECs; IBAN; mTOR
Mesh:
Substances:
Year: 2019 PMID: 31884848 PMCID: PMC7607048 DOI: 10.1177/0300060519875371
Source DB: PubMed Journal: J Int Med Res ISSN: 0300-0605 Impact factor: 1.671
Figure 1.FPPS inhibition induced autophagy in HUVECs. (a) HUVECs treated with the FPPS inhibitor IBAN (100 µM, 12 hours) were co-transfected with RFP-LC3 and GFP-LC3 and observed under confocal microscopy (scale bar: 10 µm). Red dots represent autolysosomes and yellow dots represent autophagosomes. ***P < 0.001 and &&&P < 0.001 versus control group. (b) HUVECs were treated with different concentrations of IBAN for 24 hours. Western blotting was used to assess LC3-I, LC3-II and p62 expression. Histograms were used to display the results of western blotting analysis for LC3 (d) and p62 (f). (c) HUVECs were treated with IBAN (100 µM) for different time periods as indicated. Western blotting was used to detect LC3-I, LC3-II and p62 expression. Histograms were used to display the results of western blotting analysis for LC3 (e) and p62 (g). *P < 0.05 and **P < 0.01 versus control group, #P < 0.05 and ##P < 0.01 versus 25 µM group, †P < 0.05 versus 24 hour group and ‡P < 0.01 versus 6 hour group.
Figure 2.FPPS inhibition activates lysosomal function. (a) HUVECs were treated with IBAN (100 µM) for 12 hours and then stained with LysoTracker Red DND-99 (50 nM) for 15 minutes. Fluorescence intensity of treated cells was measured using confocal microscopy (left) or flow cytometry (right). Scale bar, 10 µm. (b) and (c) As indicated in (a), after treatment with IBAN for 12 hours, cells were stained with acridine orange staining and Magic Red (cathepsin B) and analyzed using flow cytometry. *P< 0.05 and **P< 0.01 versus control group.
Figure 3.FPPS inhibition suppresses PI3K/AKT/mTOR signalling in HUVECs. (a) HUVECs were treated with different doses of IBAN for 24 hours. Representative western blotting images are shown for phospho-PI3K, PI3K, phospho-AKT, AKT, phospho-p70S6K, p70S6K, phospho-S6 and S6. Bands were quantified via densitometry and normalized to α-tubulin. The ratios between phosphorylated proteins and total proteins are shown in c, e, g and i respectively. (b) HUVECs were treated with IBAN (100 µM) for different time periods as indicated. Cells were collected and lysed, and cell lysates were prepared for western blotting. α-tubulin was used as a loading control. Representative western blotting images are shown for phospho-PI3K, PI3K, phospho-AKT, AKT, phospho-p70S6K, p70S6K, phospho-S6 and S6. Bands were quantified via densitometry and normalized to α-tubulin. The ratios between phosphorylated proteins and total proteins are shown in d, f, h and j, respectively. *P < 0.05 and **P < 0.01 versus control group, #P < 0.05 and ##P < 0.01 versus 25 µM group, †P < 0.05 and ††P < 0.01versus 24 hour group, ‡P < 0.01 versus 6 hour group and ΔP < 0.01 versus 12 hour group.
Figure 4.FPPS inhibition potentiates cell growth inhibition via impairment of autophagy. HUVECs were treated with IBAN (100 µM) with or without chloroquine (25 µM) for 24 hours. (a,b) Morphological changes of HUVECs following treatments were visualized using an inverted microscope (scale bar: 20 µm). (c) Cell proliferation was assessed using an MTS assay. The formazan dye produced by viable cells was quantified by measuring absorbance at 490 nm. (d) HUVECs were transiently transfected with an Atg7-specific siRNA. HUVECs were subsequently treated with IBAN (100 µM) for 24 hours, and cell proliferation was assessed using an MTS assay. *P< 0.05, **P< 0.01. (e) Western blotting was used to confirm Atg7 knockdown. Histograms were used to display the results of western blotting analysis. **P < 0.01 versus control group.